Outcomes of epilepsy surgery in patients with diffuse gliomas of the brain

   The objectives of surgical treatment of patients with diff use brain gliomas include achieving control over epileptic seizures and improving quality of life, in addition to prolonging relapse-free period and life duration.

   The aim of the research is to study the factors that determine the eff ectiveness of epilepsy surgery in patients with diffuse brain gliomas.

   Material and methods. The study group comprised 104 patients with diff use brain gliomas, aged 41.21 ± 14.74. Results of author’s research. Clinical, neuroimaging and morphological factors were studied. Of the studied group of 104 patients with diffuse brain gliomas who had been diagnosed with epilepsy prior to surgery, the remission of 6 months after surgery was achieved in 58 (55.77 %) patients and of 12 months in 55 (52.88 %) patients. The development of acute symptomatic epileptic seizures (p = 0.68067) and acute symptomatic status epilepticus (p = 0.41626) in post-operative period do not determine the outcomes of epilepsy surgery. Neither the histological subtype of the diffuse brain gliomas, nor the molecular-genetic factor (IDH1/2 mutation, 1p/19q codeletion) determines the outcomes of epilepsy surgery in this patient category. The group of antiepileptic medications or the medication regimen (monotherapy, two-drug therapy) also does not determine the surgery outcomes. The factors that determine a favorable outcome of surgical treatment for epilepsy in patients with diff use brain gliomas are complete tumor removal and involvement of brain commissures after magnetic resonance imaging before surgery.

   Conclusion. The effectiveness of epilepsy surgery is determined by the radical removal of the diff use brain glioma, thereby eliminating the glutamate-mediated mechanisms of epileptogenesis.

1. Prokudin M.Yu., Odinak M.M., Litvinenko I.V., Martynov B.V., Svistov D.V., Bushurov S.E., Klitsenko O.A. Clinical and morphological risk factors for the development of epilepsy in patients with glial and metastatic brain tumors. S.S. Korsakov journal of neurology and psychiatry. 2020;120(11):22–28. (In Russ.). doi: 10.17116/jnevro202012011122

2. Kholyavin A.I., Nizkovolos V.B., Martynov B.V., Svistov D.V., Anichkov A.D., Alekseeva N.P. Possibilities of Using Cryosurgical Method in Treatment of Depth Brain Tumors. Grekov’s Bulletin of Surgery. 2016;175(1):11–17. (In Russ.)

3. Poddubnaya I.V., Yakhno N.N., Martynov A.I., Nasonov E.L., Lila A.M., Nevzorova D.V. et al. Diagnosis and rational therapy of chronic pain in cancer patients. Journal of modern oncology. 2018;20(2):5–17. (In Russ.)]. https://elibrary.ru/item.asp?id=35359017

4. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classifi cation of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi: 10.1007/s00401-007-0243-4

5. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. (Eds). WHO Classification of Tumours of the Central Nervous System. Revised 4th edition. IARC: Lyon; 2016:408 р.

6. Wieser H.G., Blume W.T., Fish D., Goldensohn E., Hufnagel A., King D. et al. Commission on Neurosurgery of the International League Against Epilepsy (ILAE). ILAE Commission Report. Proposal for a new classifi cation of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia. 2001;42(2):282–286.

7. Englot D.J., Berger M.S., Barbaro N.M., Chang E.F. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011;115(2):240–4. doi: 10.3171/2011.3.JNS1153

8. Zaatreh M.M., Firlik K.S., Spencer D.D., Spencer S.S. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. Neurology. 2003;61(5):636–641. doi: 10.1212/01.wnl.0000079374.78589.1b

9. Ollila L., Roivainen R. Glioma features and seizure control during long-term follow-up. Epilepsy Behav Rep. 2023;21:100586. doi: 10.1016/j.ebr.2023.100586

10. Borger V., Hamed M., Ilic I., Potthoff A.L., Racz A., Schäfer N. et al. Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional grosstotal resection. J Neurooncol. 2021;152(2):339–346. doi: 10.1007/s11060-021-03705-x

11. Tan M., Boston R., Cook M.J., D’Souza W.J. Risk factors for injury in a community-treated cohort of patients with epilepsy in Australia. Epilepsia. 2019;60(3):518–526. doi: 10.1111/epi.14659

12. You G., Sha Z.Y., Yan W., Zhang W., Wang Y.Z., Li S.W. et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol. 2012;14(2):230–241. doi: 10.1093/neuonc/nor205

13. Feyissa A.M., Worrell G.A., Tatum W.O., Chaichana K.L., Jentoft M.E., Guerrero Cazares H., et al. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. Seizure. 2019;69:283–289. doi: 10.1016/j.seizure.2019.05.018

14. Tan Z.R., Long X.Y., Yang Z.Q., Huang J., Hu Q.Y., Yang H.D., Li G.L. Younger age at surgery and lesser seizure frequency as prognostic factors for favorable seizure-related outcome after glioma resection in adults. Oncotarget. 2017;8(55):93444–93449. doi: 10.18632/oncotarget.18726

15. Chang E.F., Potts M.B., Keles G.E., Lamborn K.R., Chang S.M., Barbaro N.M., Berger M.S. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108(2):227–235. doi: 10.3171/JNS/2008/108/2/0227

16. Drumm M.R., Wang W., Sears T.K., Bell-Burdett K., Javier R., Cotton K.Y., et al. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors. J Clin Invest. 2023;133(12):e168035. doi: 10.1172/JCI168035

17. He X., Zhang K., Liu D., Yang Z., Li X., Yang Z. Predictors of seizure outcomes in patients with diff use low-grade glioma-related epilepsy after complete glioma removal. CNS Neurosci Ther. 2023;29(2):736–743. doi: 10.1111/cns.14061

18. Englot D.J., Han S.J., Berger M.S., Barbaro N.M., Chang E.F. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012;70(4):921–928. doi: 10.1227/NEU.0b013e31823c3a30

19. Prokudin M.Yu., Martynov B.V., Yakovenko A.I., Litvinenko I.V., Lobzin V.Yu., Svistov D.V. et al. The role of glutamine synthetase expression and cystine/glutamate transporter (slc7a11, xct) in epilepsy pathogenesis of patients with supratentorial brain gliomas. Epilepsy and Paroxysmal Conditions. 2022;14(2):204–213. (In Russ.). doi: 10.17749/2077-8333/epi.par.con.2022.118